KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Equity Ratio (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Equity Ratio data on record, last reported at 0.78 in Q4 2025.

  • For Q4 2025, Equity Ratio rose 27.19% year-over-year to 0.78; the TTM value through Dec 2025 reached 0.78, up 27.19%, while the annual FY2025 figure was 0.78, 27.19% up from the prior year.
  • Equity Ratio reached 0.78 in Q4 2025 per ACAD's latest filing, up from 0.69 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.79 in Q3 2021 and bottomed at 0.54 in Q1 2024.
  • Average Equity Ratio over 5 years is 0.67, with a median of 0.68 recorded in 2025.
  • Peak YoY movement for Equity Ratio: dropped 19.85% in 2023, then rose 27.19% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.77 in 2021, then decreased by 11.83% to 0.68 in 2022, then decreased by 15.37% to 0.58 in 2023, then grew by 7.02% to 0.62 in 2024, then grew by 27.19% to 0.78 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.78 in Q4 2025, 0.69 in Q3 2025, and 0.67 in Q2 2025.